Jennifer L. Alejo
www.ncbi.nlm.nih.gov
0000-0003-3137-9271
NYU Langone Health
6 papers found
Refreshing results…
Neutralizing activity and 3-month durability of tixagevimab and cilgavimab prophylaxis against Omicron sublineages in transplant recipients
Patient‐reported outcomes after Tixagevimab and Cilgavimab pre‐exposure prophylaxis among solid organ transplant recipients: Safety, effectiveness, and perceptions of risk
6‐month antibody kinetics and durability after four doses of a SARS‐CoV‐2 vaccine in solid organ transplant recipients
Antibody response to a third dose of SARS‐CoV‐2 vaccine in heart and lung transplant recipients
Heterologous Ad.26.COV2.S versus homologous BNT162b2/mRNA-1273 as a third dose in solid organ transplant recipients seronegative after two-dose mRNA vaccination
Improved humoral immunogenicity with mRNA‐1273 versus BNT162b2 as third vaccine dose among solid organ transplant recipients seronegative after two BNT162b2 doses
Missing publications? Search for publications with a matching author name.